Silexion Therapeutics【SLXN】銘柄情報

Silexion Therapeutics Corporation (SLXN) 銘柄情報

個人投資家向けのプロ仕様のツール。

プレミアム

通貨

2.52

( -3.45% )

買値

2.51

売値

2.59

出来高

14,806

平均取引量 (3 か月)

US$ 639,055

財務取引量

US$ 37,928

2.51 日の範囲 2.65

0.231 52 週間の範囲 22.36

時価総額

1.056M

企業価値

684.241k

前日終値

2.61

始値

2.65

時刻

2.52

最終取引時間

VWAP

2.5616

歳入

純利益

-12.91M

発行済株式数

418,995

浮動株比率 (%)

98.96%

機関投資家保有比率 (%)

4.53%

配当利回り

PER

-0.04

株価売上高倍率 (PSR)

1 株当たり利益 (EPS)

-63.78

ベータ

-0.26

Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise... Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. Silexion Therapeutics Corp has collaboration with Evonik Corporation for the development of an advanced siRNA formulation to enhance cancer treatment. The company was founded in 2008 and is headquartered in Jerusalem, Israel. 詳細を表示

セクター

業界

ウェブサイト

silexion.com

本社

Jerusalem, Israel

設立

2026

Silexion Therapeutics Corporation is listed in the sector of the ナスダック市場 with ticker SLXN. The last closing price for Silexion Therapeutics was US$2.61. Over the last year, Silexion Therapeutics shares have traded in a share price range of US$ 0.231 to US$ 22.36.

Silexion Therapeutics currently has 418,995 shares in issue. The market capitalisation of Silexion Therapeutics is US$1.06 million. Silexion Therapeutics has a price to earnings ratio (PE ratio) of -0.04.

Silexion Therapeutics Receives Approval from Germany's BfArM to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer

CTA Approval from Germany's Federal Institute for Drugs and Medical Devices (BfArM), accompanied by a positive...

Silexion Therapeutics Announces 1-for-10 Reverse Share Split

Grand Cayman, May 26, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the...

Silexion Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Israeli Ministry of Health approved the initiation of Silexion's Phase 2/3 clinical trial of SIL204 in locally...

Silexion Therapeutics Announces Exercise of Warrants for $1 Million Gross Proceeds

Grand Cayman, May 15, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the...

Silexion Therapeutics Reports Positive Preliminary Immunotherapy Findings for SIL204 in KRAS-Driven Pancreatic Cancer

Grand Cayman, Cayman Islands, May 14, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN...

Silexion Therapeutics Announces Initiation of GMP Clinical Supply Manufacturing of SIL204 with Leading Global CDMO, and New Approval of Phase 2/3 Trial From Tel Aviv Sourasky Medical Center

Silexion advances toward Phase 2/3 trial in KRAS-driven pancreatic cancer, as SIL204 begins GMP clinical...

Silexion Therapeutics Announces Successful Submission of Phase 2/3 Clinical Trial Application to Germany’s BfArM for SIL204 in KRAS-Driven Locally Advanced Pancreatic Cancer

Grand Cayman, Cayman Islands, April 28, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN...

Silexion Therapeutics Receives Approval from Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer

Significant regulatory milestone marks advancement into clinical-stage development of next-generation RNAi...

Silexion Therapeutics Receives Approval from Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer

Significant regulatory milestone marks advancement into clinical-stage development of next-generation RNAi...

Silexion Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Throughout the year, the Company reported significant positive preclinical findings for SIL204 across eight...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	-0.12	-4.54545454545	2.64	2.85	2.5	19583	2.73086056	CS
4	-0.62	-19.7452229299	3.14	3.26	2.33	150740	2.73958885	CS
12	1.51	149.504950495	1.01	5.45	0.231	6231111	0.55776121	CS
26	0.45	21.7391304348	2.07	5.45	0.231	2913881	0.56669762	CS
52	1.67	196.470588235	0.85	22.36	0.231	1586029	0.96178063	CS
156	-1.48	-37	4	22.36	0.207	3732878	1.4192568	CS
260	-1.48	-37	4	22.36	0.207	3732878	1.4192568	CS